Compare Stocks: IBO, TLSA, NGEN, and AVXL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$1.49 -3.2%	$2.71	$1.44 ▼ $9.53	$142.75M	1.17	1.20 million shs	1.29 million shs
IBO Impact Biomedical	$4.25 +3.4%	$5.79	$4.06 ▼ $10.47	$35.10M	2.74	14,890 shs	4,014 shs
NGEN NervGen Pharma	$1.73 -1.1%	$1.96	$1.58 ▼ $6.30	$141.10M	N/A	479,509 shs	293,179 shs
TLSA Tiziana Life Sciences	$1.19 +5.3%	$1.02	$0.76 ▼ $2.25	$143.80M	0.45	682,694 shs	2.42 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+0.65%	-18.52%	-45.96%	-38.40%	-84.37%
IBO Impact Biomedical	-8.26%	-24.31%	-34.87%	-26.32%	-47.25%
NGEN NervGen Pharma	+0.57%	-0.57%	-20.09%	-6.91%	+174,999,900.00%
TLSA Tiziana Life Sciences	+2.73%	-0.88%	+14.18%	-8.13%	-50.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$1.49 -3.2%	$2.71	$1.44 ▼ $9.53	$142.75M	1.17	1.20 million shs	1.29 million shs
IBO Impact Biomedical	$4.25 +3.4%	$5.79	$4.06 ▼ $10.47	$35.10M	2.74	14,890 shs	4,014 shs
NGEN NervGen Pharma	$1.73 -1.1%	$1.96	$1.58 ▼ $6.30	$141.10M	N/A	479,509 shs	293,179 shs
TLSA Tiziana Life Sciences	$1.19 +5.3%	$1.02	$0.76 ▼ $2.25	$143.80M	0.45	682,694 shs	2.42 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+0.65%	-18.52%	-45.96%	-38.40%	-84.37%
IBO Impact Biomedical	-8.26%	-24.31%	-34.87%	-26.32%	-47.25%
NGEN NervGen Pharma	+0.57%	-0.57%	-20.09%	-6.91%	+174,999,900.00%
TLSA Tiziana Life Sciences	+2.73%	-0.88%	+14.18%	-8.13%	-50.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	2.40	Hold	$21.33	1,331.77% Upside
IBO Impact Biomedical	0.00	N/A	N/A	N/A
NGEN NervGen Pharma	2.83	Moderate Buy	$14.00	709.25% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest IBO, TLSA, NGEN, and AVXL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	AVXL Anavex Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/26/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/4/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	NGEN NervGen Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	TLSA Tiziana Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/13/2026	NGEN NervGen Pharma	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.10 per share	N/A
IBO Impact Biomedical	$30K	1,209.83	N/A	N/A	$1.88 per share	2.26
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	$0.03 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$46.38M	-$0.15	N/A	N/A	N/A	N/A	-11.43%	-10.72%	11/24/2026 (Estimated)
IBO Impact Biomedical	-$11.84M	N/A	N/A	N/A	N/A	2,254.28%	8.81%	4.49%	N/A
NGEN NervGen Pharma	-$31.58M	-$0.46	N/A	N/A	N/A	N/A	-1,259.82%	-199.79%	N/A
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IBO, TLSA, NGEN, and AVXL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.08	$0.08	+$0.16	$0.08	N/A	N/A
8/13/2026	Q2 2026	NGEN NervGen Pharma	-$0.09	-$0.37	-$0.28	-$0.37	N/A	N/A
8/7/2026	Q2 2026	IBO Impact Biomedical	N/A	-$0.1262	N/A	-$0.01	N/A	$0.00 million
7/30/2026	Q2 2026	AVXL Anavex Life Sciences	-$0.07	-$0.06	+$0.01	-$0.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
IBO Impact Biomedical	N/A	N/A	N/A	N/A	N/A
NGEN NervGen Pharma	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	15.62	15.62
IBO Impact Biomedical	N/A	0.16	0.13
NGEN NervGen Pharma	N/A	1.23	1.23
TLSA Tiziana Life Sciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
IBO Impact Biomedical	N/A
NGEN NervGen Pharma	N/A
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
IBO Impact Biomedical	89.00%
NGEN NervGen Pharma	5.80%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	34	92.70 million	82.13 million	Optionable
IBO Impact Biomedical	8	8.54 million	939,000	N/A
NGEN NervGen Pharma	8	80.63 million	75.95 million	N/A
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable

IBO, TLSA, NGEN, and AVXL Headlines

Recent News About These Companies

Tiziana Life Sciences (TLSA) Gets a Buy from BTIG

October 7 at 1:24 AM | theglobeandmail.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Lowered by Wall Street Zen

October 3, 2026 | marketbeat.com

Tiziana Files For Orphan Drug Designation For Foralumab In MSA

September 30, 2026 | rttnews.com

Tiziana Seeks FDA Orphan Drug Designation For Intranasal Foralumab

September 30, 2026 | rttnews.com

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

September 30, 2026 | proactiveinvestors.com

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

September 30, 2026 | finance.yahoo.com

Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trial

September 30, 2026 | finance.yahoo.com

Tiziana Life Sciences, Ltd. Announces First Participants Dosed In ALS BANYAN Clinical Trial Of Intranasal Foralumab

September 29, 2026 | marketscreener.comM

Tiziana Begins Phase 2a BANYAN Trial Of Intranasal Foralumab In ALS Patients

September 28, 2026 | rttnews.com

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

September 28, 2026 | proactiveinvestors.com

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

September 28, 2026 | markets.businessinsider.com

Tiziana Life Sciences Completes Last Patient Last Visit in Phase 2A Inform-Ms Trial of Intranasal Foralumab

September 22, 2026 | marketscreener.comM

BTIG Research Reaffirms "Buy" Rating for Tiziana Life Sciences (NASDAQ:TLSA)

September 22, 2026 | marketbeat.com

Tiziana Doses Final Patient In Phase 2a INFORM-MS For Foralumab; Topline Data In Oct '26

September 21, 2026 | rttnews.com

Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October

September 21, 2026 | finance.yahoo.com

Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

September 21, 2026 | markets.businessinsider.com

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

September 21, 2026 | proactiveinvestors.com

Tiziana Life Sciences Ltd(NasdaqCM:TLSA) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Why is Tiziana Life Sciences stock gaining Thursday?

September 17, 2026 | msn.com

Tiziana Signs MOU With KAIMRC To Advance Foralumab MS Trials; Stock Up

September 17, 2026 | rttnews.com

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

September 17, 2026 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IBO, TLSA, NGEN, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$1.49 -0.05 (-3.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.53 +0.04 (+2.68%)

As of 07:30 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Impact Biomedical NYSEAMERICAN:IBO

$4.25 +0.14 (+3.41%)

Closing price 04:10 PM Eastern

Extended Trading

$4.28 +0.03 (+0.59%)

As of 07:42 PM Eastern

Impact Biomedical, Inc. (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc., which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. Currently, our operations are conducted, and our assets are owned through our principal subsidiaries: (i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) Impact BioLife Science (“Impact BioLife”), which was incorporated on August 28, 2020, (iii) Global BioMedical, Inc. (“Global BioMedical”), which was incorporated on April 18, 2017, and (iv) Sweet Sense, Inc. (“Sweet Sense”), which was incorporated on April 30, 2018. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals and over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. In addition to our existing efforts, we continually search for and evaluate other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBIO technologies in exchange for milestone, and royalty licensing payments. Below is a list of our principal subsidiaries: . Impact BioLife Science, Inc.; . Global Biomedical, Inc.; . Global BioLife, Inc.; and . Sweet Sense, Inc. Impact BioLife Science, Inc. We are the sole owner of the outstanding equity of Impact BioLife Science, Inc. Global Biomedical, Inc. We own 90.9% of Global Biomedical, Inc.’s outstanding equity. Global BioLife, Inc. Through our majority owned subsidiary Global Biomedical, Inc., we own 81.8% of the outstanding equity of Global BioLife, Inc. Sweet Sense, Inc. We are the owner of 95.5% of the outstanding equity of Sweet Sense. Impact BioMedical Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 1400 Broadfield Blvd., Suite 130, Houston, Texas.

NervGen Pharma NASDAQ:NGEN

$1.73 -0.02 (-1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$1.73 0.00 (0.00%)

As of 07:30 PM Eastern

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Tiziana Life Sciences NASDAQ:TLSA

$1.19 +0.06 (+5.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 -0.01 (-0.92%)

As of 07:30 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBO, TLSA, NGEN, and AVXL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBO, TLSA, NGEN, and AVXL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBO, TLSA, NGEN, and AVXL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IBO, TLSA, NGEN, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Impact Biomedical NYSEAMERICAN:IBO

NervGen Pharma NASDAQ:NGEN

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBO, TLSA, NGEN, and AVXL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBO, TLSA, NGEN, and AVXL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBO, TLSA, NGEN, and AVXL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IBO, TLSA, NGEN, and AVXL Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Impact Biomedical NYSEAMERICAN:IBO

NervGen Pharma NASDAQ:NGEN

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools